Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).


Journal

Acta clinica Belgica
ISSN: 2295-3337
Titre abrégé: Acta Clin Belg
Pays: England
ID NLM: 0370306

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 2 4 2021
medline: 31 5 2022
entrez: 1 4 2021
Statut: ppublish

Résumé

Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.In line with international allergy societies, the Belgian Society for Allergy and Clinical Immunology (BelSACI) provides this statement to guide health care providers (general practitioners, specialists including allergists) and stakeholders.In this statement, we first review current evidence on allergic reactions to vaccines and the potential risk factors that have been identified.Second, we provide a risk stratification method that may be used as a worksheet during the vaccination campaign.Finally, we discuss the management of suspected or confirmed allergic reactions following vaccination.

Identifiants

pubmed: 33792500
doi: 10.1080/17843286.2021.1909447
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

552-557

Auteurs

Sebastiaan Tuyls (S)

Pulmonology Department, Sint Augustinus Ziekenhuis GZA, Antwerpen and UZ Leuven, Leuven, Belgium.

Xavier Van Der Brempt (X)

Pulmonology Department and Allergopôle, Clinique Saint-Luc, Bouge, Belgium.

Margaretha Faber (M)

Allergology and Immunology Department, World Allergy Organization (WAO) Center of Excellence, Universitaire Ziekenhuizen Antwerpen and Universiteit Antwerpen, Antwerpen, Belgium.

Romy Gadisseur (R)

Clinical Biology Department, CHU Liège and Université de Liège, Liège, Belgium.

Bita Dezfoulian (B)

Dermatology Department, CHU Liège and Université de Liège, Liège, Belgium.

Rik Schrijvers (R)

KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.

Antoine Froidure (A)

Pulmonology Department, WAO Center of Excellence, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Bruxelles, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH